Medicine Platform

CC-930(Tanzisertib)

  • 收藏 0

Price

  • $988.19元/

上海东苍生物科技有限公司
13906606503 13906606503
  • 发货地  Syrian Arab Republic
  • 品 牌  东苍生物
本公司精品橱窗推荐
  • 资本:未填写
  • 类型:企业单位
  • 主营:
  • 地区:Syrian Arab Republic
本页信息为上海东苍生物科技有限公司为您提供的“CC-930(Tanzisertib)”产品信息,如您想了解更多关于“CC-930(Tanzisertib)”价格、型号、厂家,请联系厂家,或给厂家留言。
询价 暂无
发货 Syrian Arab Republic
品牌 东苍生物
过期 长期有效
更新 2025-08-12 14:53

CC-930(Tanzisertib)

CC-930(Tanzisertib)是JNK1,JNK2和JNK3抑制剂,IC50分别为61,7和6 nM,已针对纤维化和炎症等适应症进入临床实验。

CC-930的生物活性

CC-930(Tanzisertib) is a selective and potent JNK1/JNK2/JNK3(IC50=61/7/6 nM) inhibitor and is currently under clinical development for fibrotic and infammatory indications.
IC50 Value: 61 nM (JNK1); 7 nM (JNK2); 6 nM (JNK3) [1]
Target: JNK1/2/3
in vitro: Compound 1 (CC-930) showed remarkable selectivity in a panel of 240 kinases, EGFR being the only non-MAP kinase inhibited more than 50% at 3 lM (IC50 = 0.38 lM). It inhibited no receptor at greater than 50% at 10 lM concentration in a panel of 75 receptors, ion channels and neurotransmitter transporters. Finally, when tested against 22 diverse non-kinase enzymes at 10 lM, no inhibition greater than 50% was observed [1]. Incubation with CC-930 prevented the phosphorylation of c-Jun and reduced the stimulatory levels of these cytokines on the release of collagen [2].
in vivo: Inhibition of JNK by CC-930 prevented dermal thickening, myofibroblast differentiation and the accumulation of collagen in a dose-dependent manner in mice challenged with bleomycin and in TSK1 mice. In addition to the prevention of fibrosis, treatment with pharmacologically relevant doses of CC-930 also induced regression of established experimental fibrosis [2]. CC-930 did not affect blood pressure, kidney hypertrophy, glomerular hyperfiltration, podocyte loss, glomerular fibrosis or tubulointerstitial injury in diabetic SHR (spontaneously hypertensive rats). However, CC-930 reduced macrophages and ccl2 mRNA levels in diabetic kidneys [3].
Toxicity: There were no deaths or AEs that led to withdrawal during the study. Fifteen (33%) subjects reported a total of 22 treatment-emergent adverse events (TEAEs). Subject 207 (25-mg CC-930 group) was involved in a road traffic accident 6 days after the dose and was hospitalized. This adverse event was considered as a serious adverse event but not related to the study drug. The severity of all other adverse events was rated as mild [4].

化学信息

分子量 448.44 储存条件 参考CoA中推荐的条件进行储存。
分子式 C21H23F3N6O2
CAS号 899805-25-5
溶剂/溶解度 10 mM in DMSO
公司名 上海东苍生物科技有限公司 经营模式未填写
注册资本未填写 公司注册时间2012年
公司所在地Syrian Arab Republic 企业类型企业单位 ()
主营行业
主营产品或服务
联系方式
 
Disclaimer:
当前页为价格信息展示,该页所展示的批发价格、报价等相关信息均有企业自行提供,价格真实性、准确性、合法性由店铺所有企业完全负责。Medicine Platform对此不承担任何保证责任。
Reminder:
建议您通过拨打厂家联系方式确认最终价格,并索要样品确认产品质量。如报价过低,可能为虚假信息,请确认报价真实性,谨防上当受骗。